The US FDA will not add more staff to eliminate its backlog of orphan drug designation requests and return review times to the status quo.
An orphan designation makes a drug sponsor eligible for several incentives, including seven years of marketing exclusivity upon approval and tax credits for clinical trial costs. FDA's 90 In...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?